Markets:

Overview

News

Currencies

International

Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

106.66 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Jan 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

25 26 Next >

3 Pharma Stocks Could Be the Pills Your Portfolio Needs ↗

January 18, 2024

These large-cap pharma stocks offer growth and value with existing medicines, deep pipelines and reasonable valuations.

Via InvestorPlace

Analyst Highlights Aclaris Therapeutics' Encouraging Efficacy For Eczema Candidate, But Cautions On Data Variations ↗

January 10, 2024

Wednesday, Aclaris Therapeutics Inc (NASDAQ: ACRS) released topline results from its Phase 2b study of ATI-1777, an investigational topical "soft" JAK 1/3 inhibitor, in patients with mild to

Via Benzinga

In the world of growth stocks, NASDAQ:INCY shines as a value proposition. ↗

January 10, 2024

Investors seeking growth at a reasonable cost should explore INCYTE CORP (NASDAQ:INCY).

Via Chartmill

Incyte Highlights Growth Opportunities and Provides Business Updates at the 42nd Annual J.P. Morgan Healthcare Conference

January 08, 2024

From Incyte

Via Business Wire

For those who appreciate value investing, NASDAQ:INCY is a compelling option with its solid fundamentals. ↗

December 28, 2023

In a market where value is scarce, INCYTE CORP (NASDAQ:INCY) offers a refreshing opportunity with its solid fundamentals.

Via Chartmill

Expert Ratings for Incyte ↗

December 13, 2023

Via Benzinga

What's Up With Incyte Stock Lately? ↗

December 12, 2023

Incyte Corporation (NASDAQ: INCY) shares are trading higher on Tuesday. The stock has risen rapidly since Monday.

Via Benzinga

Despite its impressive fundamentals, NASDAQ:INCY remains undervalued. ↗

December 06, 2023

Despite its impressive fundamentals, INCYTE CORP (NASDAQ:INCY) remains undervalued.

Via Chartmill

NASDAQ:INCY is showing decent growth, but is still valued reasonably. ↗

December 19, 2023

For those who appreciate growth without the sticker shock, INCYTE CORP (NASDAQ:INCY) is worth considering.

Via Chartmill

AI Meets Biotech: 3 Top Stocks Transforming Medical Science ↗

December 16, 2023

The AI revolution is bringing big gains to biotechnology, including drugs, antibodies, and synthetic biology.

Via InvestorPlace

Topics Artificial Intelligence

The 3 Most Undervalued Biotech Stocks to Buy in December ↗

December 15, 2023

Biotech is an increasing area of interest in the financial markets, line your portfolio up with these winning biotech stocks.

Via InvestorPlace

Incyte to Present at Upcoming Investor Conferences

December 12, 2023

From Incyte

Via Business Wire

Incyte and Syndax Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease

December 10, 2023

From Incyte and Syndax Pharmaceuticals

Via Business Wire

The Latest Analyst Ratings for Incyte ↗

November 21, 2023

Via Benzinga

Looking for growth without the hefty price tag? Consider NASDAQ:INCY. ↗

November 06, 2023

Looking for growth without the hefty price tag? Consider INCYTE CORP (NASDAQ:INCY).

Via Chartmill

S&P 500's Hidden Gems: 27 Stocks With 30%+ Upside Potential According To Wall Street Analysts Targets ↗

December 07, 2023

Fifty-six percent of S&P 500 companies have shown positive performance in 2023 and 44% retreated Moderna Inc. (NASDAQ: MRNA) offers the highest upside potential (58%).

Via Benzinga

Topics Stocks

Investors should take note of NASDAQ:INCY, a growth stock that remains attractively priced. ↗

November 28, 2023

Investors should take note ofINCYTE CORP (NASDAQ:INCY), a growth stock that remains attractively priced.

Via Chartmill

Goldman Sachs Downgrades Incyte Amid Concerns Over Jakafi Studies, Competitiveness ↗

November 21, 2023

Goldman Sachs downgraded Incyte Corp (NASDAQ: INCY), citing continued uncertainty around Jakafi (Ruxolitinib) lifecycle management ahead of the mid-27/late-28 EU/US

Via Benzinga

Earnings Outlook For Incyte ↗

October 30, 2023

Via Benzinga

Investors should take notice of NASDAQ:INCY—it offers a great deal for the fundamentals it presents. ↗

November 14, 2023

Investors should take notice ofINCYTE CORP (NASDAQ:INCY)—it offers a great deal for the fundamentals it presents.

Via Chartmill

3 Biotech Stocks That Are Poised to Have Breakthroughs in 2024 ↗

November 12, 2023

Investors should consider these "Goldilocks" biotech stocks to buy as they are poised to get significant boosts next year.

Via InvestorPlace

7 Underappreciated Biotech Stocks to Pick Up on the Cheap ↗

November 09, 2023

With questions rising about the economy, investors may consider undervalued biotech stocks for their relative insulation factor.

Via InvestorPlace

Topics Economy

Goldman Sachs Maintains Buy Rating for Incyte: Here's What You Need To Know ↗

November 02, 2023

Via Benzinga

Incyte to Spotlight More Than 40 Hematology and Oncology Abstracts Including a Plenary Presentation at the ASH Annual Meeting

November 02, 2023

From Incyte

Via Business Wire

Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs

October 31, 2023

From Incyte

Via Business Wire

Science Magazine Recognizes Incyte as #2 “Top Employer” of 2023

October 27, 2023

From Incyte

Via Business Wire

NASDAQ:INCY stands out as a stock that provides good value for the fundamentals it showcases. ↗

October 23, 2023

INCYTE CORP (NASDAQ:INCY) appears to be flying under the radar despite its strong fundamentals.

Via Chartmill

Incyte to Present at Upcoming Investor Conferences

October 18, 2023

From Incyte

Via Business Wire

Incyte Announces New Data from across its Oncology Portfolio to be Presented at ESMO Congress 2023

October 16, 2023

From Incyte

Via Business Wire

Incyte Announces New Data for Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis

October 13, 2023

From Incyte

Via Business Wire

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

25 26 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.